The new Center is focused on outpacing the rising threat of antimicrobial resistance (AMR) and builds on Johnson & Johnson’s longstanding commitment to tackle this challenge
The Satellite Center in Cape Town is the second site to open in Johnson & Johnson’s network of research collaborations aimed at addressing the world’s most pressing health challenges
The collaboration between Johnson & Johnson and H3D will help to further expand and strengthen Africa’s scientific capacity as a global hub for discovery research
CAPE TOWN, South Africa, April 25, 2022 /PRNewswire/ — Johnson & Johnson (the Company) (NYSE: JNJ) today announced the launch of the J&J Satellite Center for Global Health Discovery (Satellite Center) at the Holistic Drug Discovery and Development (H3D) Centre, University of Cape Town, in Cape Town, South Africa. This marks the latest expansion of the J&J Centers for Global Health Discovery (J&J Centers), a global network of research collaborations between the Company and leading research institutions to accelerate translational and discovery research to address some of the world’s most pressing global health challenges. The Satellite Center at H3D will work to drive new solutions to address the present and rising threat of antimicrobial resistance (AMR) with a specific focus on multidrug-resistant Gram-negative bacteria (MDR-GNB).
The establishment of the J&J Centers is a critical step in the creation of a larger, global scientific network that will help stimulate local innovation and support researchers to drive and advance discovery research and development (R&D). Together, teams from the Janssen Pharmaceutical Companies of Johnson & Johnson and H3D will leverage their combined global, institutional and regional strengths to bolster the early-stage science, innovation and talent development needed to tackle AMR, a prevalent threat in Africa and around the world.
“Investing to increase the capacity of the innovation ecosystem in Africa is critical to strengthening the R&D pipeline for entrenched and emerging global health challenges,” said Ruxandra Draghia-Akli, M.D., Ph.D., Global Head, Global Public Health R&D at Janssen Research & Development, LLC. “By leveraging the unique strengths of H3D and the J&J Centers, we can cultivate the talent and capacity needed to drive innovation in the global fight against AMR.”
AMR has been named one of the top ten global health threats by the World Health Organization (WHO) and has the power to transform easily treated diseases into deadly killers by rendering medicines and medical innovations ineffective. In 2019, more than 5 million deaths were attributed to AMR, making it one of the leading causes of death worldwide. MDR Gram-negative bacteria are particularly concerning to public health because of their resistance to multiple antibiotics and the limited availability of treatment options. Currently, all three of the resistant bacteria described as critical priority level by the WHO are Gram-negative.
“Antibiotics have been the backbone of modern medicine for more than a century, but increasing resistance threatens to render them ineffective,” said Anil Koul, Ph.D., Vice President of Discovery and Partnerships, Global Public Health R&D at Janssen Research & Development, LLC. “Our innovation in new antibiotic drug discovery must outpace this rising threat, and the new Satellite Center will build on Johnson & Johnson’s legacy in AMR and H3D’s expertise to help deliver this ambition more quickly to people in need.”
The AMR challenge is particularly acute in Africa as well as Asia, where the transmission of pneumonia, diarrheal diseases, tuberculosis (TB), malaria and sexually transmitted infections, coupled with limited data surveillance, has created an environment where significant resistance to antibiotics can develop. Furthermore, local researchers have long faced systemic barriers to accessing the support, resources and infrastructure as well as new technological platforms that are key to tackling significant health challenges like AMR.
“We must come together to advance investment in African-led innovation to protect the health of both our communities and the world,” said Kelly Chibale, Ph.D., Founder and Director of H3D. “It is critical that local researchers have the opportunity to investigate the challenges that impact their communities, without having to leave those communities. Being embedded in local communities, H3D is uniquely positioned to provide this opportunity. This collaboration will further foster the talent and provide the tools and opportunity needed to create innovative solutions in public health.”
About the J&J Centers for Global Health Discovery
Johnson & Johnson is joining forces with renowned institutions and leveraging their regional networks to bolster innovation and health equity in parallel through the establishment of the J&J Centers for Global Health Discovery. The Satellite Centers will provide long-term opportunities for mentorship of emerging talent in the discovery sciences to stimulate both local innovation and capacity.
Johnson & Johnson launched the first Satellite Center in July 2021 at the London School of Hygiene & Tropical Medicine (LSHTM), which is focused on developing cutting-edge science to build the next-generation of drug regimens needed to treat all forms of tuberculosis (TB). The disease remains one of the most significant challenges in global health, responsible for 1.5 million deaths in 2020 and accounting for nearly one-third of all deaths from AMR.
The risk of intense epidemics is growing rapidly, with the probability of novel disease outbreaks likely to increase three-fold in the coming decades. Despite this, the last decade has seen a consistent decline in funding for basic science. The J&J Centers are an important step in turning this tide and delivering innovations needed to address the diseases that disproportionately impact the world’s poorest and most vulnerable people.
Additional Satellite Centers will be launched in the future. To learn more, visit jnj.com/global-public-health/discovery-centers.
Johnson & Johnson’s Efforts to Outpace Antimicrobial Resistance
Research at the new Satellite Center will build on Johnson & Johnson’s decades of work accelerating innovation – from the lab to the last mile of healthcare – to outpace the threat of AMR. As a founding member of the AMR Action Fund and AMR Industry Alliance, Johnson & Johnson has committed to investing in and advancing critical science, as well as providing access to antibiotics and safeguarding their long-term effectiveness, to meet public health needs. As part of these efforts, the Janssen Pharmaceutical Companies of Johnson & Johnson are leading the pursuit for novel vaccines and therapeutics to tackle a range of drug-resistant infections, including drug-resistant TB and E. coli.
To learn more, visit, JNJ.com/AMR.
A Deep and Enduring Commitment to Africa
Since Johnson & Johnson first opened its doors in South Africa 90 years ago, the Company has been committed to transforming the health of people living in the country and across the continent, helping lead the charge against some of the most significant health threats in the region, like COVID-19, TB, HIV and Ebola.
Critically, Johnson & Johnson has responded to the COVID-19 pandemic by expanding capacity in Africa. In March 2022, Janssen Pharmaceuticals, Inc. completed a landmark agreement with Aspen Pharmacare in South Africa to transfer its fill-and-finish manufacturing technology, allowing the first COVID-19 vaccine to be manufactured and sold by an African company for people living in Africa. In addition to building manufacturing capacity, the Janssen Pharmaceutical Companies of Johnson & Johnson included sites in Africa for its COVID-19 vaccine clinical trials, supported a large-scale COVID-19 vaccine implementation study in South Africa and was the first major manufacturer to sign a purchase agreement to supply its vaccine to African Union countries.
About Johnson & Johnson
At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That’s why for more than 130 years, we have aimed to keep people well at every age and every stage of life. Today, as the world’s largest and most broadly-based healthcare company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity. Learn more at www.jnj.com. Follow us at @JNJNews.
About the Janssen Pharmaceutical Companies of Johnson & Johnson
At Janssen, we’re creating a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension.
Learn more at www.janssen.com. Follow us at www.twitter.com/JanssenUS and www.twitter.com/JanssenGlobal. Janssen Research & Development, LLC and Janssen Biotech, Inc. are part of the Janssen Pharmaceutical Companies of Johnson & Johnson.
Cautions Concerning Forward-Looking Statements
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding antimicrobial resistance. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of any of the Janssen Pharmaceutical Companies and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended January 2, 2022, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. None of the Janssen Pharmaceutical Companies nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.
SOURCE Johnson & Johnson